Clinical Trial Update: Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

View source ↗

Summary

A non-invasive prenatal genotyping and extraction technology for diagnosing and treating hemolytic disease of the newborn has received marketing approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Disease of the Newborn

Snippet

Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine | Conditions: HDFN | Status: APPROVED_FOR_MARKETING